NCT04841369: Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) |
|
|
| Completed | 3 | 3420 | RoW | 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, PCV13i, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, Prevnar | CanSino Biologics Inc., Henan Center for Disease Control and Prevention | Pneumococcal Infections, Streptococcal Infections, Bacterial Infections | 03/22 | 09/22 | | |
NCT05091619: A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed |
|
|
| Active, not recruiting | 3 | 2898 | RoW | Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed, DTacP, Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed, DTaP, Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine, PENTAXIM | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. | Whooping Cough, Diphtheria, Tetanus | 09/23 | 09/27 | | |
NCT04982068: Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 |
|
|
| Active, not recruiting | 1 | 72 | RoW | 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose, Placebo | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. | COVID-19 | 10/21 | 06/23 | | |
